Human Reticular Acellular Dermal Matrix in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover …
Wounds: a Compendium of Clinical Research and Practice, 2017•europepmc.org
Background Acellular matrices have been successfully used to heal indolent diabetic foot
ulcers (DFUs). These tissues include allogenic dermis as well as xenograft dermis,
pericardium, and small intestine submucosa. While all of these tissues show promise for
healing DFUs, dermal-derived matrices have shown considerable potential. Materials and
methods The authors retrospectively reviewed healing in patients with DFUs that failed the
standard of care (SOC) treatment from a previous prospective randomized, controlled trial …
ulcers (DFUs). These tissues include allogenic dermis as well as xenograft dermis,
pericardium, and small intestine submucosa. While all of these tissues show promise for
healing DFUs, dermal-derived matrices have shown considerable potential. Materials and
methods The authors retrospectively reviewed healing in patients with DFUs that failed the
standard of care (SOC) treatment from a previous prospective randomized, controlled trial …
Background
Acellular matrices have been successfully used to heal indolent diabetic foot ulcers (DFUs). These tissues include allogenic dermis as well as xenograft dermis, pericardium, and small intestine submucosa. While all of these tissues show promise for healing DFUs, dermal-derived matrices have shown considerable potential.
Materials and methods
The authors retrospectively reviewed healing in patients with DFUs that failed the standard of care (SOC) treatment from a previous prospective randomized, controlled trial (RCT). That trial compared the efficacy of human reticular acellular dermal matrices (HR-ADMs) with the SOC. Of the 16 out of 20 patients who did not heal in the SOC group, 12 were eligible for crossover treatment with the HR-ADM. The authors studied the rate of complete healing in that specific cohort after 12 weeks of crossover treatment.
Results
Of the 12 patients who were eligible for the HR-ADM, 10 (83%) achieved complete wound healing, with a mean healing time of 21 days to closure. The corresponding wound area reduction was from 1.7 cm2 to 0.6 cm2. The mean product cost to closure was $800/patient.
Conclusion
This study further demonstrates the effectiveness of the HR-ADM in facilitating the closure of nonhealing DFUs refractory to SOC.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果